KRAS G12C in Colorectal Cancer: Biomarker Context

What KRAS G12C Changes

KRAS is a small GTPase that relays signals from receptors such as EGFR to downstream MAPK and PI3K pathways. G12C changes the switch region around codon 12 and reduces normal control of the active and inactive states. The altered protein can therefore keep sending growth and survival signals even when upstream signalling is reduced.

The cysteine created by G12C is chemically useful for a class of covalent KRAS inhibitors. That does not make all KRAS variants interchangeable: G12D, G12V, G13D, and other substitutions have different biochemical properties and different evidence bases.

Why Colorectal Cancer Is Its Own Context

In colorectal cancer, EGFR feedback and pathway reactivation can influence how a KRAS G12C tumour responds to a targeted drug. That is one reason treatment evidence from KRAS G12C lung cancer should not be copied directly into colorectal cancer. The histology, previous lines of therapy, and combination strategy are part of the evidence—not details to be left out of a summary.

A pathology report may also include RAS status, BRAF status, microsatellite or mismatch-repair findings, and other co-alterations. Those results can change the clinical question and are why a single mutation should be interpreted as one part of a molecular profile.

The FDA Treatment Statement, Precisely Scoped

The FDA announcement cited below describes accelerated approval of adagrasib plus cetuximab for adults with KRAS G12C-mutated, locally advanced or metastatic colorectal cancer after treatment with a fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, when the mutation is detected by an FDA-approved test. That is a specific labelled population and regimen; it is not a recommendation for every KRAS mutation, stage, or prior-treatment history.

Accelerated approval also means the evidence and confirmatory obligations remain part of the regulatory story. Readers should use the current label and clinician guidance for decisions, because indications, safety information, and testing requirements can change. GeneAnalyses provides a map to the evidence rather than a prescribing instruction.

Testing and Resistance Boundaries

KRAS G12C can be detected by targeted PCR or NGS in tumour tissue, and sometimes by plasma circulating-tumour-DNA testing. The report should retain the exact variant, specimen, assay, quality metrics, and limit of detection. A non-detected plasma result can be uninformative when little tumour DNA is shed.

Resistance may involve on-target KRAS changes, renewed upstream signalling, or parallel pathway alterations. Progression therefore does not automatically mean the original result was a false positive. It is a reason for a clinician-led review of the disease course and whether repeat testing could answer a new question.

Key Takeaways

• ·KRAS G12C is a specific codon-12 substitution; it should not be treated as shorthand for every KRAS mutation.
• ·Colorectal-cancer evidence is not interchangeable with evidence from KRAS G12C lung cancer.
• ·The FDA source is limited to a defined advanced-disease, prior-therapy, combination-treatment, and test setting.
• ·Keep the full molecular profile because EGFR, BRAF, mismatch-repair, and other findings can alter the next question.